samedan logo
 
 

spacer
home > ebr
PUBLICATIONS

European Biopharmaceutical Review
 

European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America & the rest of the world.

With editorial consisting of in-depth articles, case studies, meeting and report reviews written by specialists with hands-on experience in the biopharmaceutical industry, traditional multi-national pharmaceutical companies, investment houses and industry-associated governmental, economic and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with regular feature sections on BioBusiness Development, Research and Innovation, BioDiscovery, BioManufacturing plus special focuses on geographic or therapeutic territories.

For further information please contact:

Editorial

Jasmin Collier


 

 

 
  

Connect with us on Twitter: follow @EBRmagazine

Read our publications on the go in the Samedan app for iPhone and iPad. You can download issues for offline reading and our archives go as far back as 2008! Download for free on the App Store.

View the
digital version
of EBR

ebr
 
 
Featured in this issue
RESEARCH AND DEVELOPMENT
According to Nicola J McCarthy and Jonathan D Moore at Horizon Discovery, the field of immuno-oncology is rapidly advancing due to the use of the CRISPR-Cas9 system. This technology can improve both treatment and patient benefit.
Drug Discovery
There has been considerable growth in the use of virus-like particles across the whole pharma landscape, observes ARTES Biotechnology’s Volker Jenzelewski. These can aid new results and can contribute to safe and efficacious vaccines.
  CELL-BASED RESEARCH
CellGenix’s Bernd Leistler reminds the pharma community that rules and regulations continue to tighten, and that it is important to maintain high quality levels in raw materials, in order to ensure the safety and efficacy of any therapy.

spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October


 

Industry Events

Clinical Trial Supply Southern California 2016

15-16 November 2016, San Diego, CA

Over 45% of biotechnology medicines in development today are being created by biopharmaceutical companies with major operations in California - notably San Diego which is one of the leading biotech hubs in the US.
More info >>

 
News and Press Releases

Merck to Showcase Innovative Excipients and Emprove® Program at CPhI Worldwide


More info >>

air transport logo
Air Transport Publications

 

White Papers

Quality of Steel

Natoli Engineering Company, Inc.

Steel quality is the summation of how well a steel meets its specified chemistry, the cleanliness of the steel or degree to which it is free of impurities or inclusion, homogeneity of the microstructure, grain/carbide size and in some instances if it meets the mechanical requirements for that particular steel. In the design and manufacture of tablet compression tooling, nothing is more important than the quality of the materials being used. The best manufacturing principals maintaining the tightest tolerances will result in tool failure if the initial material quality is poor. Material quality is the fundamental building block upon which all successive value added steps are laid. The majority of all tablet compression tooling is produced from steel and steel quality is the subject of this article.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page
Send to a friend
Privacy statement